Wall Street Pulls Back on the Weight-Loss Drug Hype - Barron's

1. Analysts predict growing demand for GLP-1 obesity drugs despite market uncertainties. 2. Goldman Sachs cut global weight-loss drug market forecast, impacting LLY's outlook. 3. LLY acquiring significant market share, expected to maintain competitive position. 4. Price decline in U.S. expected, but potential for higher sales volumes globally. 5. Goldman Sachs upgraded LLY to 'Buy', targeting $888 per share.